0.10Open0.10Pre Close0 Volume21 Open Interest5.00Strike Price0.00Turnover346.09%IV54.08%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.1772Delta0.2118Gamma33.10Leverage Ratio-0.0373Theta0.0001Rho5.87Eff Leverage0.0009Vega
Mural Oncology Stock Discussion
NEWS
Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting
Mural Oncology presented data from its ARTISTRY-3 trial at the ASCO annual meeting, showing that less frequent dosing of nemvaleukin alfa (nemvaleukin), an engineered IL-2 cytokine, is well-tolerated and effective.
The trial shifted from five daily infusions to two infusions per three-week cycle, both as a single agent and in combination with pembrolizu...
NEWS
Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting
👃
👄
$Mural Oncology(MURA.US)$
No comment yet